Business
Totaligent Announces Formation of Joint Venture with GloMed Solutions to Commercialize Advanced Biologics in Japan and APAC
Strategic Partnership Combines Aetherium Medical Platform with GloMed’s Established APAC Distribution Network; Advances Totaligent’s Entry into High-Growth Medical Tourism and Biologics MarketsBOCA RATON, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), today announced the formation of a 50/50 joint venture between its wholly owned subsidiary, Aetherium Medical LLC, and GloMed Solutions Limited Liability Company (“GloMed”), a Japanese company
About this update from Totaligent Inc.
[{"type":"image","alt":"Totaligent","displaySize":"","headline":null,"caption":"Totaligent","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/c8bedb384e3c0d364748274b591abf13"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/38VZ_BCGc0hjij0S9WP4xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOA--/https://media.zenfs.com/en/globenewswire.com/c8bedb384e3c0d364748274b591abf13","width":300,"height":77},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/38VZ_BCGc0hjij0S9WP4xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOA--/https://media.zenfs.com/en/globenewswire.com/c8bedb384e3c0d364748274b591abf13","width":300,"height":77}},"lazy":false},{"type":"text","content":"Strategic Partnership Combines Aetherium Medical Platform with GloMed’s Established APAC Distribution Network; Advances Totaligent’s Entry into High-Growth Medical Tourism and Biologics Markets","length":193,"tagName":"p"},{"type":"text","content":"BOCA RATON, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Totaligent, Inc. (OTCID: TGNT) (“Totaligent” or “the Company”), today announced the formation of a 50/50 joint venture between its wholly owned subsidiary, Aetherium Medical LLC, and GloMed Solutions Limited Liability Company (“GloMed”), a Japanese company with a proven distribution network in the Asia-Pacific region.","length":370,"tagName":"p"},{"type":"text","content":"The Joint Venture, effective May 22, 2026, integrates Aetherium’s proprietary medical platform—including its dual-track regulatory strategy, intellectual property, know-how, and commercialization infrastructure—with GloMed’s established distribution infrastructure, which includes relationships with over 20 key opinion leaders and specialty clinics across high-growth APAC markets. The combined entity will focus on the rapid commercialization of advanced biologics and medical devices in Japan and the broader APAC region through ethical and efficient medical tourism channels.","length":579,"tagName":"p"},{"type":"text","content":"“This joint venture represents a major milestone in Totaligent’s strategy to become a leader at the intersection of innovative biologics and medical tourism,” said Ivan Klarich, President of Totaligent. “By combining Aetherium’s cutting-edge platform with GloMed’s established on-the-ground presence and revenue-generating network in ...